🔬Deep Research

AIM — AIM ImmunoTech Inc · catalysts, narrative & risks

·15 sourcesAIM forecast →

AIM ImmunoTech Inc. (NYSE American: AIM)

Recent Catalysts (roughly July–October 2026)

The most significant recent activity centers on the company's lead candidate Ampligen® (rintatolimod) and its pancreatic cancer program:


AI-assisted research from the K3vl4r desk — not personalized investment advice. More research →